Form 8-K

8-K — UNITED THERAPEUTICS Corp

Accession: 0001104659-26-086068

Filed: 2026-07-23

Period: 2026-07-22

CIK: 0001082554

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2620809d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2620809d1_ex99-1.htm)

GRAPHIC (tm2620809d1_ex99-1img001.jpg)

GRAPHIC (tm2620809d1_ex99-1img002.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2620809d1_8k.htm · Sequence: 1

false

0001082554

2026-07-22

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of

the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

July 22, 2026

United Therapeutics Corporation

(Exact Name of Registrant as Specified in

its Charter)

Delaware

000-26301

52-1984749

(State or Other

(Commission

(I.R.S. Employer

Jurisdiction of

File Number)

Identification Number)

Incorporation)

1000 Spring Street

Silver Spring, MD

20910

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including

area code: (301) 608-9292

Check the appropriate box below if the Form 8-K filing

is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities

Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange

Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under

the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under

the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant

to Section 12(b) of the Act:

Title of each class

Trading symbol(s)

Name of each exchange on which

registered

Common Stock, par value $0.01 per share

UTHR

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging

growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of

the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ¨

If an emerging

growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with

any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of

Certain Officers.

On July 22, 2026, the Board of Directors (the Board)

of United Therapeutics Corporation (the Company), acting upon the recommendation of its Nominating and Governance Committee, increased

the size of the Board to 13 members and appointed Victor Dzau, M.D., to serve as a member of the Board. The Board determined that Dr.

Dzau will not serve on a Board committee initially.

There is no arrangement or understanding between Dr. Dzau and any other

persons pursuant to which he was selected as a director of the Company. Since the beginning of the Company’s last fiscal year through

the present, there have been no transactions with the Company, and there are currently no proposed transactions with the Company, in which

the amount involved exceeds $120,000 and in which Dr. Dzau had or will have a direct or indirect material interest within the meaning

of Item 404(a) of Regulation S-K.

In connection with Dr. Dzau’s appointment to the Board, the

Company awarded him the following awards under the Company’s 2026 Stock Incentive Plan: (a) 380 restricted stock units and

1,190 stock options, representing his initial grant upon joining the Board, and (b) 350 restricted stock units and 1,110 stock

options, which are pro-rata grants representing the remainder of the 2026-2027 Board service year. These awards were

granted on July 22, 2026, in accordance with the Company’s standard non-employee director compensation program (the Director

Compensation Program), as described in the Company’s definitive proxy statement for its 2026 annual meeting of

shareholders, filed with the Securities and Exchange Commission (SEC) on April 29, 2026. Dr. Dzau will be provided further

compensation for his services in accordance with the Director Compensation Program. Dr. Dzau and the Company also entered into the

Company’s standard indemnification agreement for directors and executive officers, effective July 22, 2026, the form of which

was filed with the SEC as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed October 1, 2021.

Item 7.01. Regulation FD Disclosure.

A copy of the press release announcing Dr. Dzau’s appointment

is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information in this Item 7.01 and Exhibit

99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange

Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated

by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act as amended, regardless of any general incorporation

language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description of Exhibit

99.1

Press Release dated July 23, 2026

104

Cover page Interactive Data File - the cover page XBRL tags are embedded within the inline XBRL document.

SIGNATURE

Pursuant to the requirements of the Securities

Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly

authorized.

UNITED THERAPEUTICS CORPORATION

Dated: July 23, 2026

By:

/s/ Paul A. Mahon

Name:

Paul A. Mahon

Title:

General Counsel

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2620809d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

United Therapeutics

Corporation Announces Appointment of Victor Dzau to its Board of Directors

SILVER SPRING,

Md. and DURHAM, N.C., July 23, 2026 — United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced

today that the company’s Board of Directors appointed Victor Dzau, M.D., to its Board on July 22, 2026.

Dr. Dzau recently

completed a 12-year tenure as President of the National Academy of Medicine (NAM) and formerly served as Chancellor for Health

Affairs at Duke University, President and CEO of the Duke University Health System, and Chairman of Medicine at Harvard and Stanford

Universities. His term with NAM expired at the end of June 2026, and in July 2026 he returned to Duke University as James B. Duke Distinguished

Professor of Medicine, Chancellor Emeritus for Health Affairs, and Director of the Mandel Center. He also serves as Co-Chair of the G20

High-Level Independent Panel on Financing Pandemic Preparedness and Response.

He is recognized

globally for a highly decorated career as a physician-scientist and leader. His research laid the foundation for lifesaving drugs known

as ACE inhibitors. He pioneered gene therapy for vascular disease and is now studying cardiac regeneration.

“Dr.

Dzau is a visionary healthcare leader, with a storied career both nationally and internationally. I am honored he has joined our Board,

and believe he is uniquely capable of guiding United Therapeutics in our public benefit mission of developing transplantable organs and

organ alternatives for patients suffering from many forms of end-stage organ failure,” said Martine Rothblatt, Ph.D., Chairperson

and Chief Executive Officer of United Therapeutics.

“I have

admired United Therapeutics’ mission and progress over its 30-year history, and am thrilled to join its Board of Directors at one

of the company’s most exciting moments. I look forward to supporting United Therapeutics as it pursues groundbreaking treatments

for rare diseases and the bold mission of pioneering biomedical and bioengineering breakthroughs to help address the severe shortage

of transplantable organs,” said Dr. Dzau.

“I am excited to add Dr. Dzau’s

voice to our boardroom, and look forward to benefiting from his deep knowledge, experience, and insights in our industry and the healthcare

system as a whole,” said Christopher Causey, Chairperson of the Nominating and Governance Committee of United Therapeutics’

Board of Directors. “Dr. Dzau’s addition to our Board is the latest step in our concerted Board refreshment effort, as we

work to provide oversight and support of a company working on transforming patient care.”

About United Therapeutics

Founded by CEO Martine Rothblatt to

discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the

treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to

our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies

that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with

integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build.

Visit us at www.unither.com and follow us on LinkedIn, Facebook,

and Instagram.

Forward-Looking Statements

Statements

included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the

Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others,

statements regarding our public benefit mission of developing transplantable organs and organ alternatives

for patients suffering from many forms of end-stage organ failure, our ongoing Board refreshment efforts, the anticipated contributions

of Dr. Dzau to our Board, our pursuit of groundbreaking treatments for rare diseases, our mission

of pioneering biomedical and bioengineering breakthroughs to address the severe shortage of transplantable organs, our efforts

to transform patient care, our goals of expanding the supply of transplantable organs, developing practical technologies that can save

lives, creating long-term shareholder value, and operating with sustainable practices. These forward-looking statements are subject

to certain risks and uncertainties, such as those described in our periodic reports filed with

the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently,

such forward-looking statements are qualified by the cautionary statements, cautionary language,

and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most

recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe

harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information

as of July 23, 2026, and assume no obligation to update or revise the information contained in this press release whether because of

new information, future events or any other reason.

For Further Information Contact:

Investor Inquiries

https://ir.unither.com/contact-ir

Media Inquiries

communications@unither.com

GRAPHIC

Filename: tm2620809d1_ex99-1img001.jpg · Sequence: 3

Binary file (2606 bytes)

Download tm2620809d1_ex99-1img001.jpg

GRAPHIC

Filename: tm2620809d1_ex99-1img002.jpg · Sequence: 4

Binary file (38957 bytes)

Download tm2620809d1_ex99-1img002.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Jul. 22, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 22, 2026

Entity File Number

000-26301

Entity Registrant Name

United Therapeutics Corporation

Entity Central Index Key

0001082554

Entity Tax Identification Number

52-1984749

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1000 Spring Street

Entity Address, City or Town

Silver Spring

Entity Address, State or Province

Entity Address, Postal Zip Code

20910

City Area Code

301

Local Phone Number

608-9292

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.01 per share

Trading Symbol

UTHR

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration